ID TTBK2_HUMAN Reviewed; 1244 AA. AC Q6IQ55; O94932; Q6ZN52; Q8IVV1; DT 16-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 24-JAN-2024, entry version 179. DE RecName: Full=Tau-tubulin kinase 2; DE EC=2.7.11.1; GN Name=TTBK2; Synonyms=KIAA0847; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Cerebellum; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT RP PRO-8. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 600-1244 (ISOFORM 1). RC TISSUE=Brain; RX PubMed=10048485; DOI=10.1093/dnares/5.6.355; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:355-364(1998). RN [5] RP INVOLVEMENT IN SCA11. RX PubMed=18037885; DOI=10.1038/ng.2007.43; RA Houlden H., Johnson J., Gardner-Thorpe C., Lashley T., Hernandez D., RA Worth P., Singleton A.B., Hilton D.A., Holton J., Revesz T., Davis M.B., RA Giunti P., Wood N.W.; RT "Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, RT segregate with spinocerebellar ataxia type 11."; RL Nat. Genet. 39:1434-1436(2007). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR RP LOCATION, AND MUTAGENESIS OF LYS-50; LYS-143; ASP-163; ARG-181 AND ALA-184. RX PubMed=21548880; DOI=10.1042/bj20110276; RA Bouskila M., Esoof N., Gay L., Fang E.H., Deak M., Begley M.J., RA Cantley L.C., Prescott A., Storey K.G., Alessi D.R.; RT "TTBK2 kinase substrate specificity and the impact of spinocerebellar- RT ataxia-causing mutations on expression, activity, localization and RT development."; RL Biochem. J. 437:157-167(2011). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-786, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [8] RP INTERACTION WITH CEP164. RX PubMed=22863007; DOI=10.1016/j.cell.2012.06.028; RA Chaki M., Airik R., Ghosh A.K., Giles R.H., Chen R., Slaats G.G., Wang H., RA Hurd T.W., Zhou W., Cluckey A., Gee H.Y., Ramaswami G., Hong C.J., RA Hamilton B.A., Cervenka I., Ganji R.S., Bryja V., Arts H.H., RA van Reeuwijk J., Oud M.M., Letteboer S.J., Roepman R., Husson H., RA Ibraghimov-Beskrovnaya O., Yasunaga T., Walz G., Eley L., Sayer J.A., RA Schermer B., Liebau M.C., Benzing T., Le Corre S., Drummond I., Janssen S., RA Allen S.J., Natarajan S., O'Toole J.F., Attanasio M., Saunier S., RA Antignac C., Koenekoop R.K., Ren H., Lopez I., Nayir A., Stoetzel C., RA Dollfus H., Massoudi R., Gleeson J.G., Andreoli S.P., Doherty D.G., RA Lindstrad A., Golzio C., Katsanis N., Pape L., Abboud E.B., Al-Rajhi A.A., RA Lewis R.A., Omran H., Lee E.Y., Wang S., Sekiguchi J.M., Saunders R., RA Johnson C.A., Garner E., Vanselow K., Andersen J.S., Shlomai J., RA Nurnberg G., Nurnberg P., Levy S., Smogorzewska A., Otto E.A., RA Hildebrandt F.; RT "Exome capture reveals ZNF423 and CEP164 mutations, linking renal RT ciliopathies to DNA damage response signaling."; RL Cell 150:533-548(2012). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=23141541; DOI=10.1016/j.cell.2012.10.010; RA Goetz S.C., Liem K.F. Jr., Anderson K.V.; RT "The spinocerebellar ataxia-associated gene tau tubulin kinase 2 controls RT the initiation of ciliogenesis."; RL Cell 151:847-858(2012). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-445 AND SER-1103, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP FUNCTION. RX PubMed=30375385; DOI=10.1038/s41467-018-06990-9; RA Huang N., Zhang D., Li F., Chai P., Wang S., Teng J., Chen J.; RT "M-Phase Phosphoprotein 9 regulates ciliogenesis by modulating CP110-CEP97 RT complex localization at the mother centriole."; RL Nat. Commun. 9:4511-4511(2018). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] PRO-8; GLN-120; ALA-313; MET-440; PRO-500; RP GLY-635; ILE-1062; MET-1084; ALA-1097; ARG-1122 AND THR-1241. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP VARIANTS PRO-8; GLY-842 AND HIS-1110. RX PubMed=19533200; DOI=10.1007/s00415-009-5209-0; RA Edener U., Kurth I., Meiner A., Hoffmann F., Hubner C.A., Bernard V., RA Gillessen-Kaesbach G., Zuhlke C.; RT "Missense exchanges in the TTBK2 gene mutated in SCA11."; RL J. Neurol. 256:1856-1859(2009). RN [14] RP VARIANTS ILE-367 AND GLU-724. RX PubMed=26063658; DOI=10.1093/brain/awv155; RA Verdura E., Herve D., Scharrer E., del Mar Amador M., Guyant-Marechal L., RA Philippi A., Corlobe A., Bergametti F., Gazal S., Prieto-Morin C., RA Beaufort N., Le Bail B., Viakhireva I., Dichgans M., Chabriat H., RA Haffner C., Tournier-Lasserve E.; RT "Heterozygous HTRA1 mutations are associated with autosomal dominant RT cerebral small vessel disease."; RL Brain 138:2347-2358(2015). CC -!- FUNCTION: Serine/threonine kinase that acts as a key regulator of CC ciliogenesis: controls the initiation of ciliogenesis by binding to the CC distal end of the basal body and promoting the removal of CCP110, which CC caps the mother centriole, leading to the recruitment of IFT proteins, CC which build the ciliary axoneme. Has some substrate preference for CC proteins that are already phosphorylated on a Tyr residue at the +2 CC position relative to the phosphorylation site. Able to phosphorylate CC tau on serines in vitro (PubMed:23141541). Phosphorylates MPHOSPH9 CC which promotes its ubiquitination and proteasomal degradation, loss of CC MPHOSPH9 facilitates the removal of the CP110-CEP97 complex (a negative CC regulator of ciliogenesis) from the mother centrioles, promoting the CC initiation of ciliogenesis (PubMed:30375385). CC {ECO:0000269|PubMed:21548880, ECO:0000269|PubMed:23141541, CC ECO:0000269|PubMed:30375385}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl- CC [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21548880}; CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L- CC threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, CC Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.1; Evidence={ECO:0000269|PubMed:21548880}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=18 uM for RRKDLHDDEEDEAMSIYpA peptide CC {ECO:0000269|PubMed:21548880}; CC KM=141 uM for RRKDLHDDEEDEAMSIYA peptide CC {ECO:0000269|PubMed:21548880}; CC Vmax=76 umol/min/mg enzyme with RRKDLHDDEEDEAMSIYpA peptide as CC substrate {ECO:0000269|PubMed:21548880}; CC Vmax=66 umol/min/mg enzyme with RRKDLHDDEEDEAMSIYA peptide as CC substrate {ECO:0000269|PubMed:21548880}; CC -!- SUBUNIT: Interacts with CEP164. {ECO:0000269|PubMed:22863007}. CC -!- INTERACTION: CC Q6IQ55; Q9UPV0: CEP164; NbExp=4; IntAct=EBI-1050303, EBI-3937015; CC Q6IQ55; Q53G59: KLHL12; NbExp=6; IntAct=EBI-1050303, EBI-740929; CC Q6IQ55-3; Q9UNS2: COPS3; NbExp=3; IntAct=EBI-25930156, EBI-350590; CC Q6IQ55-3; Q9GZS3: SKIC8; NbExp=3; IntAct=EBI-25930156, EBI-358545; CC -!- SUBCELLULAR LOCATION: Cell projection, cilium {ECO:0000250}. Cytoplasm, CC cytoskeleton, cilium basal body {ECO:0000250}. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome, centriole. Cytoplasm, CC cytosol. Nucleus. Note=Localizes to the transition zone in primary CC cilia in response to cell cycle signals that promote ciliogenesis (By CC similarity). May also be present in cytosol and, at lower level in the CC nucleus. {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q6IQ55-1; Sequence=Displayed; CC Name=2; CC IsoId=Q6IQ55-2; Sequence=VSP_018272, VSP_018275; CC Name=3; CC IsoId=Q6IQ55-3; Sequence=VSP_018273, VSP_018274; CC -!- DISEASE: Spinocerebellar ataxia 11 (SCA11) [MIM:604432]: CC Spinocerebellar ataxia is a clinically and genetically heterogeneous CC group of cerebellar disorders. Patients show progressive incoordination CC of gait and often poor coordination of hands, speech and eye movements, CC due to degeneration of the cerebellum with variable involvement of the CC brainstem and spinal cord. SCA11 is an autosomal dominant cerebellar CC ataxia (ADCA). It is a relatively benign, late-onset, slowly CC progressive neurologic disorder. {ECO:0000269|PubMed:18037885}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr CC protein kinase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131372; BAD18523.1; -; mRNA. DR EMBL; AC068727; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC090510; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC041876; AAH41876.1; -; mRNA. DR EMBL; BC071556; AAH71556.1; -; mRNA. DR EMBL; AB020654; BAA74870.1; -; mRNA. DR CCDS; CCDS42029.1; -. [Q6IQ55-1] DR RefSeq; NP_775771.3; NM_173500.3. [Q6IQ55-1] DR PDB; 6U0K; X-ray; 1.74 A; A/B=1-299. DR PDB; 6VRF; X-ray; 1.50 A; A/B=1-299. DR PDB; 7O3B; X-ray; 2.40 A; G/H/I=1074-1087. DR PDB; 7Q8Y; X-ray; 1.60 A; A/B=1-299. DR PDB; 7Q8Z; X-ray; 1.57 A; A/B=1-299. DR PDB; 7Q90; X-ray; 1.60 A; A/B=1-299. DR PDBsum; 6U0K; -. DR PDBsum; 6VRF; -. DR PDBsum; 7O3B; -. DR PDBsum; 7Q8Y; -. DR PDBsum; 7Q8Z; -. DR PDBsum; 7Q90; -. DR AlphaFoldDB; Q6IQ55; -. DR SMR; Q6IQ55; -. DR BioGRID; 126962; 31. DR CORUM; Q6IQ55; -. DR IntAct; Q6IQ55; 8. DR STRING; 9606.ENSP00000267890; -. DR BindingDB; Q6IQ55; -. DR ChEMBL; CHEMBL3337327; -. DR GlyCosmos; Q6IQ55; 3 sites, 1 glycan. DR GlyGen; Q6IQ55; 3 sites, 1 O-linked glycan (3 sites). DR iPTMnet; Q6IQ55; -. DR PhosphoSitePlus; Q6IQ55; -. DR BioMuta; TTBK2; -. DR DMDM; 116242833; -. DR CPTAC; non-CPTAC-6006; -. DR CPTAC; non-CPTAC-6007; -. DR EPD; Q6IQ55; -. DR jPOST; Q6IQ55; -. DR MassIVE; Q6IQ55; -. DR MaxQB; Q6IQ55; -. DR PaxDb; 9606-ENSP00000267890; -. DR PeptideAtlas; Q6IQ55; -. DR ProteomicsDB; 66487; -. [Q6IQ55-1] DR ProteomicsDB; 66488; -. [Q6IQ55-2] DR ProteomicsDB; 66489; -. [Q6IQ55-3] DR Pumba; Q6IQ55; -. DR Antibodypedia; 6214; 252 antibodies from 30 providers. DR DNASU; 146057; -. DR Ensembl; ENST00000267890.11; ENSP00000267890.6; ENSG00000128881.18. [Q6IQ55-1] DR Ensembl; ENST00000567840.5; ENSP00000455734.1; ENSG00000128881.18. [Q6IQ55-3] DR GeneID; 146057; -. DR KEGG; hsa:146057; -. DR MANE-Select; ENST00000267890.11; ENSP00000267890.6; NM_173500.4; NP_775771.3. DR UCSC; uc001zqo.4; human. [Q6IQ55-1] DR AGR; HGNC:19141; -. DR CTD; 146057; -. DR DisGeNET; 146057; -. DR GeneCards; TTBK2; -. DR GeneReviews; TTBK2; -. DR HGNC; HGNC:19141; TTBK2. DR HPA; ENSG00000128881; Tissue enhanced (testis). DR MalaCards; TTBK2; -. DR MIM; 604432; phenotype. DR MIM; 611695; gene. DR neXtProt; NX_Q6IQ55; -. DR OpenTargets; ENSG00000128881; -. DR Orphanet; 98767; Spinocerebellar ataxia type 11. DR PharmGKB; PA134913925; -. DR VEuPathDB; HostDB:ENSG00000128881; -. DR eggNOG; KOG1164; Eukaryota. DR GeneTree; ENSGT00940000160367; -. DR HOGENOM; CLU_003410_0_0_1; -. DR InParanoid; Q6IQ55; -. DR OMA; EEDWGWG; -. DR OrthoDB; 163007at2759; -. DR PhylomeDB; Q6IQ55; -. DR TreeFam; TF351646; -. DR BRENDA; 2.7.11.26; 2681. DR PathwayCommons; Q6IQ55; -. DR Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane. DR SABIO-RK; Q6IQ55; -. DR SignaLink; Q6IQ55; -. DR SIGNOR; Q6IQ55; -. DR BioGRID-ORCS; 146057; 11 hits in 1189 CRISPR screens. DR ChiTaRS; TTBK2; human. DR GeneWiki; TTBK2; -. DR GenomeRNAi; 146057; -. DR Pharos; Q6IQ55; Tbio. DR PRO; PR:Q6IQ55; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q6IQ55; Protein. DR Bgee; ENSG00000128881; Expressed in lateral nuclear group of thalamus and 193 other cell types or tissues. DR ExpressionAtlas; Q6IQ55; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:GO_Central. DR GO; GO:0036064; C:ciliary basal body; ISS:UniProtKB. DR GO; GO:0035869; C:ciliary transition zone; IDA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019894; F:kinesin binding; IPI:ARUK-UCL. DR GO; GO:0051010; F:microtubule plus-end binding; TAS:ARUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:ARUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; TAS:ARUK-UCL. DR GO; GO:0021681; P:cerebellar granular layer development; ISS:ARUK-UCL. DR GO; GO:0021935; P:cerebellar granule cell precursor tangential migration; ISS:ARUK-UCL. DR GO; GO:0021549; P:cerebellum development; ISS:ARUK-UCL. DR GO; GO:0060271; P:cilium assembly; IMP:GO_Central. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IGI:ARUK-UCL. DR GO; GO:1904527; P:negative regulation of microtubule binding; IDA:ARUK-UCL. DR GO; GO:0007026; P:negative regulation of microtubule depolymerization; IDA:ARUK-UCL. DR GO; GO:1902817; P:negative regulation of protein localization to microtubule; IMP:ARUK-UCL. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IGI:ARUK-UCL. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR GO; GO:0007224; P:smoothened signaling pathway; ISS:UniProtKB. DR CDD; cd14129; STKc_TTBK2; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR047915; TTBK2_STKc. DR PANTHER; PTHR11909; CASEIN KINASE-RELATED; 1. DR PANTHER; PTHR11909:SF451; TAU-TUBULIN KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR Genevisible; Q6IQ55; HS. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; Cilium; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; Kinase; KW Neurodegeneration; Nucleotide-binding; Nucleus; Phosphoprotein; KW Reference proteome; Serine/threonine-protein kinase; KW Spinocerebellar ataxia; Transferase. FT CHAIN 1..1244 FT /note="Tau-tubulin kinase 2" FT /id="PRO_0000234342" FT DOMAIN 21..284 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 674..694 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1052..1088 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1116..1244 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1052..1074 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1116..1133 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1134..1148 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1150..1171 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1184..1212 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1219..1244 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 141 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 27..35 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 50 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 445 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 786 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 1103 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..72 FT /note="MSGGGEQLDILSVGILVKERWKVLRKIGGGGFGEIYDALDMLTRENVALKVE FT SAQQPKQVLKMEVAVLKKLQ -> MES (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_018272" FT VAR_SEQ 470..478 FT /note="CLEKMQKDT -> WYKIVYFSF (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_018273" FT VAR_SEQ 479..1244 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_018274" FT VAR_SEQ 1233..1244 FT /note="QGKSKPASKLSR -> PREE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_018275" FT VARIANT 8 FT /note="L -> P (in dbSNP:rs6493068)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19533200" FT /id="VAR_041261" FT VARIANT 120 FT /note="R -> Q (in dbSNP:rs35328266)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041262" FT VARIANT 313 FT /note="T -> A (in dbSNP:rs56017612)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041263" FT VARIANT 367 FT /note="K -> I (in dbSNP:rs764753481)" FT /evidence="ECO:0000269|PubMed:26063658" FT /id="VAR_076383" FT VARIANT 440 FT /note="V -> M (in dbSNP:rs56311523)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041264" FT VARIANT 500 FT /note="R -> P (in dbSNP:rs56039839)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041265" FT VARIANT 635 FT /note="D -> G (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041266" FT VARIANT 724 FT /note="G -> E (in dbSNP:rs201524659)" FT /evidence="ECO:0000269|PubMed:26063658" FT /id="VAR_076384" FT VARIANT 842 FT /note="E -> G (found in a patient with SCA11; uncertain FT significance; dbSNP:rs202004988)" FT /evidence="ECO:0000269|PubMed:19533200" FT /id="VAR_069052" FT VARIANT 1062 FT /note="T -> I (in dbSNP:rs55833708)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041267" FT VARIANT 1084 FT /note="T -> M (in dbSNP:rs34348991)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041268" FT VARIANT 1097 FT /note="V -> A (in dbSNP:rs55796513)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041269" FT VARIANT 1110 FT /note="R -> H (found in a patient with SCA11; uncertain FT significance; dbSNP:rs146279300)" FT /evidence="ECO:0000269|PubMed:19533200" FT /id="VAR_069053" FT VARIANT 1122 FT /note="P -> R (in dbSNP:rs56142516)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041270" FT VARIANT 1241 FT /note="K -> T (in dbSNP:rs36104367)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041271" FT MUTAGEN 50 FT /note="K->E,A: Leads to inactivation/destabilization of the FT protein." FT /evidence="ECO:0000269|PubMed:21548880" FT MUTAGEN 143 FT /note="K->E,A: Leads to inactivation/destabilization of the FT protein." FT /evidence="ECO:0000269|PubMed:21548880" FT MUTAGEN 163 FT /note="D->A: Abolishes serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:21548880" FT MUTAGEN 181 FT /note="R->E,A: Impaired serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:21548880" FT MUTAGEN 184 FT /note="A->E,G: Impaired serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:21548880" FT CONFLICT 309 FT /note="T -> I (in Ref. 1; BAD18523)" FT /evidence="ECO:0000305" FT CONFLICT 456 FT /note="T -> A (in Ref. 1; BAD18523)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="K -> N (in Ref. 1; BAD18523)" FT /evidence="ECO:0000305" FT TURN 18..20 FT /evidence="ECO:0007829|PDB:6VRF" FT STRAND 21..28 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:6U0K" FT STRAND 34..40 FT /evidence="ECO:0007829|PDB:6VRF" FT TURN 41..44 FT /evidence="ECO:0007829|PDB:6VRF" FT STRAND 45..53 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 61..70 FT /evidence="ECO:0007829|PDB:6VRF" FT TURN 71..73 FT /evidence="ECO:0007829|PDB:6VRF" FT STRAND 80..85 FT /evidence="ECO:0007829|PDB:6VRF" FT STRAND 87..95 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 101..106 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 109..111 FT /evidence="ECO:0007829|PDB:7Q8Z" FT HELIX 115..134 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 144..146 FT /evidence="ECO:0007829|PDB:6VRF" FT STRAND 147..149 FT /evidence="ECO:0007829|PDB:6VRF" FT TURN 153..157 FT /evidence="ECO:0007829|PDB:6VRF" FT STRAND 159..161 FT /evidence="ECO:0007829|PDB:6VRF" FT STRAND 175..177 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 190..192 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 195..198 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 205..221 FT /evidence="ECO:0007829|PDB:6VRF" FT TURN 225..228 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 232..241 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 244..250 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 255..264 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 273..286 FT /evidence="ECO:0007829|PDB:6VRF" FT HELIX 296..298 FT /evidence="ECO:0007829|PDB:7Q8Z" SQ SEQUENCE 1244 AA; 137412 MW; EAB8FC28370966DE CRC64; MSGGGEQLDI LSVGILVKER WKVLRKIGGG GFGEIYDALD MLTRENVALK VESAQQPKQV LKMEVAVLKK LQGKDHVCRF IGCGRNDRFN YVVMQLQGRN LADLRRSQSR GTFTISTTLR LGRQILESIE SIHSVGFLHR DIKPSNFAMG RFPSTCRKCY MLDFGLARQF TNSCGDVRPP RAVAGFRGTV RYASINAHRN REMGRHDDLW SLFYMLVEFV VGQLPWRKIK DKEQVGSIKE RYDHRLMLKH LPPEFSIFLD HISSLDYFTK PDYQLLTSVF DNSIKTFGVI ESDPFDWEKT GNDGSLTTTT TSTTPQLHTR LTPAAIGIAN ATPIPGDLLR ENTDEVFPDE QLSDGENGIP VGVSPDKLPG SLGHPRPQEK DVWEEMDANK NKIKLGICKA ATEEENSHGQ ANGLLNAPSL GSPIRVRSEI TQPDRDIPLV RKLRSIHSFE LEKRLTLEPK PDTDKFLETC LEKMQKDTSA GKESILPALL HKPCVPAVSR TDHIWHYDEE YLPDASKPAS ANTPEQADGG GSNGFIAVNL SSCKQEIDSK EWVIVDKEQD LQDFRTNEAV GHKTTGSPSD EEPEVLQVLE ASPQDEKLQL GPWAENDHLK KETSGVVLAL SAEGPPTAAS EQYTDRLELQ PGAASQFIAA TPTSLMEAQA EGPLTAITIP RPSVASTQST SGSFHCGQQP EKKDLQPMEP TVELYSPREN FSGLVVTEGE PPSGGSRTDL GLQIDHIGHD MLPNIRESNK SQDLGPKELP DHNRLVVREF ENLPGETEEK SILLESDNED EKLSRGQHCI EISSLPGDLV IVEKDHSATT EPLDVTKTQT FSVVPNQDKN NEIMKLLTVG TSEISSRDID PHVEGQIGQV AEMQKNKISK DDDIMSEDLP GHQGDLSTFL HQEGKREKIT PRNGELFHCV SENEHGAPTR KDMVRSSFVT RHSRIPVLAQ EIDSTLESSS PVSAKEKLLQ KKAYQPDLVK LLVEKRQFKS FLGDLSSASD KLLEEKLATV PAPFCEEEVL TPFSRLTVDS HLSRSAEDSF LSPIISQSRK SKIPRPVSWV NTDQVNSSTS SQFFPRPPPG KPPTRPGVEA RLRRYKVLGS SNSDSDLFSR LAQILQNGSQ KPRSTTQCKS PGSPHNPKTP PKSPVVPRRS PSASPRSSSL PRTSSSSPSR AGRPHHDQRS SSPHLGRSKS PPSHSGSSSS RRSCQQEHCK PSKNGLKGSG SLHHHSASTK TPQGKSKPAS KLSR //